PCSK9 loss-of-function — lower lifetime LDL
One copy of a PCSK9 loss-of-function variant detected.
You have one copy of a PCSK9 DNA change that quietly dials the gene down.
Genuinely good news, on average — associated with lifelong slightly lower LDL cholesterol and a meaningfully reduced risk of coronary artery disease.
This is genuinely good news on average — you've had slightly lower LDL ("bad") cholesterol since birth and a meaningfully lower risk of heart artery disease.
What this means
PCSK9 normally degrades the LDL receptor, limiting how much cholesterol the liver clears. Loss-of-function variants leave more LDL receptor active and lower lifetime LDL. This insight — that being born with low PCSK9 activity is protective — is what inspired the PCSK9 inhibitor drug class (evolocumab, alirocumab) used for high-risk lipid management.
Your liver pulls LDL ("bad") cholesterol out of your blood using little docks called LDL receptors. The PCSK9 protein normally chews those docks up, slowing the cleanup. A DNA change that quietly turns PCSK9 down means more docks survive, and your LDL stays lower for life. The fact that people born with low PCSK9 activity tend to be protected from heart disease is what inspired a whole class of cholesterol-lowering drugs that block PCSK9.
Caveats
- Even with this protective variant, lifestyle and other risk factors still matter.
- Most variants in PCSK9 are not loss-of-function; this entry covers the well-studied R46L variant.
- Some PCSK9 variants found in African-ancestry individuals are different (Y142X, C679X) and not captured here.